Stock Track | Moderna Soars 5.15% Pre-market on Positive Phase 3 Results for Influenza Vaccine

Stock Track
06-30

Moderna, Inc. (MRNA) stock surged 5.15% in pre-market trading on Monday following the announcement of positive Phase 3 results for its experimental influenza vaccine. The biotechnology company reported that its mRNA-1010 vaccine demonstrated superior efficacy compared to licensed standard-dose seasonal flu shots in adults aged 50 years and older.

According to the late-stage study, Moderna's mRNA-1010 achieved a stringent superiority criterion with a relative vaccine efficacy (RVE) of 26.6% in the overall study population. The vaccine showed strong efficacy against various influenza strains, including A/H1N1, A/H3N2, and the B/Victoria lineages. Notably, in participants aged 65 years and older, mRNA-1010 demonstrated an RVE of 27.4%, highlighting its potential benefits for the elderly population.

The safety and tolerability profile of mRNA-1010 were consistent with previous studies, with most adverse reactions being mild. Moderna plans to present these findings at an upcoming medical conference and engage with regulators on filing submissions for mRNA-1010. This breakthrough in influenza vaccine development could potentially strengthen Moderna's position in the vaccine market, driving investor optimism and contributing to the significant pre-market stock price increase.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10